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Abstract
Single-chain urokinase-type plasminogen activator (scu-PA) is cleaved by thrombin, resulting in an inactive molecule
called thrombin-cleaved two-chain urokinase-type plasminogen activator (tcu-PA/T). There is no knowledge about cell-
mediated inactivation of scu-PA. We have studied whether scu-PA bound to cultured human umbilical vein endothelial cells
(HUVEC) could be inactivated by thrombin. High molecular weight scu-PA was bound to HUVEC and incubated with
increasing amounts of thrombin for 30 min at 37‡C. Cell-bound urokinase-type plasminogen activator (u-PA) was released
and levels of scu-PA, tcu-PA/T and active two-chain u-PA were measured using sensitive bioimmunoassays. Cell-bound scu-
PA was efficiently inactivated by thrombin. Fifty percent inactivation of scu-PA occurred at about 0.2 nM thrombin. In the
presence of monoclonal anti-urokinase receptor IgG, at least 50% of the binding of scu-PA to HUVEC was inhibited. The
relative amount of tcu-PA/T that was generated by thrombin was not affected by the monoclonal antibody. These results
indicated that scu-PA bound to HUVEC via the urokinase receptor can be inactivated by thrombin. The efficient
inactivation of cell-bound scu-PA suggests that a cofactor for thrombin may be involved, like thrombomodulin or
glycosaminoglycans. It is concluded that scu-PA bound to the urokinase receptor on a cell surface can be inactivated by
thrombin, which may have profound effects on u-PA-mediated local fibrinolysis and extracellular proteolysis during
processes in which thrombin is also involved. ß 2000 Published by Elsevier Science B.V.
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1. Introduction
Urokinase-type plasminogen activator (u-PA)
plays an important role in extracellular proteolysis
and ¢brinolysis by converting plasminogen into plas-
min [1]. This serine protease circulates as a single-
chain precursor form (scu-PA), which can be acti-
vated into two-chain u-PA (tcu-PA) after cleavage
at Lys158^Ile159 by plasmin or other activators [1].
Cleavage of scu-PA can also result in inactivation.
Thrombin cleaves scu-PA at Arg156^Phe157, two
residues prior to the activation site, in this way gen-
erating an inactive tcu-PA form called thrombin-
cleaved tcu-PA (tcu-PA/T) [2]. The inactivation of
scu-PA has been postulated as a mechanism for pro-
tecting a fresh blood clot from early ¢brinolysis [3,4].
This process does indeed take place in vivo, as we
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have demonstrated the presence of tcu-PA/T in hu-
man body £uids under pathological conditions which
involve the production of large amounts of thrombin
[5,6].
The inactivation of scu-PA by thrombin is accel-
erated by thrombomodulin, both in a puri¢ed system
and in a plasma milieu [7^9]. Thrombomodulin is a
membrane protein on endothelial cells which forms a
1:1 complex with thrombin, in this way promoting
both the anticoagulant and anti¢brinolytic properties
of thrombin (for review see [10,11]). Not only throm-
bin, but also scu-PA can be bound to the cell surface.
One important receptor is the well-known urokinase
receptor that binds scu-PA via its amino-terminal
part [12]. Low molecular weight scu-PA which lacks
its amino-terminal part is not bound by the uroki-
nase receptor [12]. Both the urokinase receptor and
thrombomodulin may play a signi¢cant role in regu-
lating the inactivation of scu-PA by thrombin on the
cell surface. Binding of scu-PA to the urokinase re-
ceptor promotes the activation of plasminogen either
by augmentation of the intrinsic activity of scu-PA
or via reciprocal activation of scu-PA and plasmino-
gen [13^17]. Inactivation of receptor-bound scu-PA
by thrombin or the thrombin/thrombomodulin com-
plex thus may a¡ect processes that are mediated by
plasminogen activation via receptor-bound u-PA,
such as local ¢brinolysis, cell migration, tumor inva-
sion, tissue remodelling and angiogenesis [12,18,19].
However, there is no knowledge about thrombin-
mediated inactivation of scu-PA on a cell surface.
In the present study, we examined the inactivation
of scu-PA bound to cultured human endothelial cells
by thrombin.
2. Materials and methods
2.1. Materials
Penicillin/streptomycin, L-glutamine and medium
M199 were obtained from Biowitthaker (Verviers,
Belgium). Heat-inactivated newborn calf serum was
obtained from Gibco/BRL (Paisley, UK). Human
serum was prepared from pooled fresh blood of
10^20 healthy donors obtained from a local blood
bank. A crude preparation of endothelial cell growth
factor was prepared from bovine brain as described
by Maciag et al. [20]. Heparin was obtained from
Leo Pharmaceutical Products (Weesp, The Nether-
lands). Gelatin was obtained from Merck (Darm-
stadt, Germany) and tissue culture plastics from Co-
star (Cambridge, MA).
High molecular weight (HMW) single-chain uroki-
nase-type plasminogen activator (scu-PA) from a
transformed human kidney cell line was a gift from
Dr F. Hammerschmidt (Sandoz, Vienna, Austria)
[21]. Low molecular weight (LMW) scu-PA puri¢ed
from human embryonic kidney cell cultures was a
gift from Dr J. Henkin (Abbott Laboratories, Ab-
bott Park, IL) [7]. Human thrombin (speci¢c activity
of 2.9 NIH U/Wg, as indicated by the manufacturer)
and bovine serum albumin (BSA) were obtained
from Sigma Chemical Co. (St. Louis, MO). Hirudin
was obtained from Pentapharm (supplied by Kordia,
Leiden, The Netherlands). Monoclonal anti-human
urokinase receptor IgG (Moab H-2) was a gift
from Dr Weidle (Boehringer Mannheim, Penzburg)
[19,22].
2.2. Cell culture
Human umbilical vein endothelial cells (HUVEC)
were isolated, cultured and characterized as de-
scribed previously [23,24]. Cells were cultured in a
12-wells gelatin-coated (1%) culture plate until con-
£uence at 5% CO2/95% air in medium M199 supple-
mented with 2 mM L-glutamine, 20 mM Hepes
(pH 7.3), 10% heat-inactivated human serum, 10%
heat-inactivated newborn calf serum, 150 Wg/ml
crude endothelial cell growth factor, 5 U/ml heparin,
100 IU/ml penicillin and 100 Wg/ml streptomycin at
37‡C. Con£uent cells were used from passage 2.
2.3. Inactivation of HMW scu-PA or LMW scu-PA
by thrombin on HUVEC
Con£uent HUVEC cultured in 3.8 cm2 wells of a
12-well culture plate were incubated for 2 h at 37‡C
with serum-free medium. Prior to the incubation
with scu-PA, endogenous ligand bound to the uroki-
nase receptor or other binding sites was removed by
washing the cells with 50 mM glycine/HCl (pH 3.0),
100 mM NaCl for 3 min at 37‡C, followed by imme-
diate neutralization with M199 containing 1% BSA
(bu¡er A). Cells were then incubated with 1 Wg/ml
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HMW scu-PA or LMW scu-PA in bu¡er A for
30 min at 37‡C in a ¢nal volume of 400 Wl. Unbound
scu-PA was removed and increasing amounts of
thrombin (0^10 nM) in bu¡er A were added for
30 min at 37‡C in a ¢nal volume of 400 Wl. After
incubation thrombin was removed and cells were
washed once with bu¡er A supplemented with
1 ATU/ml hirudin to inhibit thrombin. Cell-bound
u-PA was released by adding 405 Wl 50 mM glycine/
HCl (pH 3.0), 100 mM NaCl, 0.1% BSA for 20 min
at 37‡C, and supernatants were collected. The super-
natants were neutralized by adding 135 Wl 150 mM
Tris, 0.4% BSA, 0.04% Tween-80 containing 4 ATU/
ml hirudin and centrifuged. Levels of tcu-PA, scu-PA
and tcu-PA/T were assessed in 25 Wl supernatant us-
ing bioimmunoassays for tcu-PA, scu-PA and tcu-
PA/T (see below) [5,26,27]. Total u-PA antigen was
determined in 20 Wl supernatant using a urokinase
ELISA [28]. As a control, the experiment with
HMW scu-PA and LMW scu-PA was also per-
formed in blank wells without HUVEC using the
conditions described above. Blank wells were not
coated with gelatin.
For both cell-containing wells and blank wells, per
thrombin concentration the total amount of bound
u-PA was calculated as the sum of the amounts of
tcu-PA, scu-PA and tcu-PA/T measured in the super-
natant. Subsequently, levels of tcu-PA, scu-PA and
tcu-PA/T were expressed as a percentage of the total
amount of bound u-PA.
2.4. E¡ect of monoclonal anti-urokinase receptor IgG
(Moab H-2) on the inactivation of HMW
scu-PA by thrombin on HUVEC
HUVEC were incubated with 1 Wg/ml HMW scu-
PA in the absence and presence of 2.5 and 10 Wg/ml
monoclonal anti-urokinase receptor IgG (Moab H-2)
in bu¡er A for 30 min at 37‡C, as described above.
Unbound scu-PA and Moab H-2 were removed and
bound scu-PA was inactivated by 0.1 nM thrombin
in bu¡er A for 30 min at 37‡C. Cell-bound urokinase
was released and levels of tcu-PA, scu-PA and tcu-
PA/T were assessed in 25 Wl supernatant using the
bioimmunoassays, as described above.
2.5. Bioimmunoassay (BIA) for tcu-PA, scu-PA and
tcu-PA/T
The inactivation of scu-PA on HUVEC was mea-
sured using a BIA for tcu-PA and scu-PA, and a BIA
for tcu-PA/T as described before [5,25,26]. In these
assays, the (potential) activity of the various u-PA
forms is measured. Brie£y, 25 Wl supernatant in du-
plicate was incubated in 96-well plates coated with
rabbit polyclonal anti-u-PA antibody. After washing,
the immobilized material was activated in parallel
wells with bu¡er (BIA for tcu-PA), 1 nM plasmin
(BIA for scu-PA) or 20 nM cathepsin C (BIA for
tcu-PA/T). Urokinase activity was determined using
Glu-plasminogen and the plasmin substrate H-D-
Val-Leu-Lys-p-nitroanilide. The levels of tcu-PA
and scu-PA were calculated from a calibration curve
obtained by serial dilutions of puri¢ed scu-PA, and
Table 1
E¡ect of thrombin on the recovery of cell-bound u-PA in the BIAs
Thrombin
(nM)
Total HMW u-PA bound
to HUVEC (pg)
Total HMW u-PA bound
to blank wells (pg)
Total LMW u-PA bound
to HUVEC (pg)
Total LMW u-PA bound
to blank wells (pg)
0 4357 þ 791 628 241 þ 31 112
0.1 3747 þ 824 619 249 þ 35 113
1 2940 þ 623 586 251 þ 27 112
10 2391 þ 763 611 238 þ 30 110
HMW scu-PA or LMW scu-PA (1 Wg/ml) were bound to HUVEC for 30 min at 37‡C in four (n = 4) and three experiments (n = 3), re-
spectively. As a control, HMW scu-PA (n = 2) and LMW scu-PA (n = 1) were also bound to blank wells without HUVEC. Blank wells
were not coated with gelatin. Cells or blank wells were subsequently incubated with increasing amounts of thrombin for 30 min at
37‡C. Cell-bound or plastic-bound u-PA was released and levels of tcu-PA, scu-PA and tcu-PA/T in the supernatants (total volume of
540 Wl) were determined using bioimmunoassays (see Section 2). The total amount of bound u-PA (mean þ S.D., n = 4 for HMW scu-
PA bound to HUVEC; mean, n = 2 for HMW scu-PA bound to blank wells ; mean þ S.D., n = 3 for LMW scu-PA bound to HUVEC;
n = 1 for LMW scu-PA bound to blank wells) was expressed as the sum of the amounts of tcu-PA, scu-PA and tcu-PA/T.
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the level of tcu-PA/T was calculated from a calibra-
tion curve obtained by serial dilutions of puri¢ed tcu-
PA/T.
2.6. Statistics
Correlations between levels of u-PA measured in
the BIA and levels of u-PA measured in the ELISA
were tested using the Pearson correlation coe⁄cient
method.
3. Results
3.1. Inactivation of scu-PA by thrombin on HUVEC
The total amount of cell-bound HMW u-PA was
calculated as the sum of the levels of tcu-PA, scu-PA
and tcu-PA/T as measured in the BIAs. The recovery
of total cell-bound HMW u-PA was found to de-
crease with increasing amounts of thrombin, while
no e¡ect was observed on the binding of HMW u-
PA to blank wells (Table 1). The same phenomenon
was found when total u-PA antigen was measured by
ELISA (data not shown). In addition, a positive cor-
relation was observed between the levels of the total
amount of u-PA recovered in the BIAs and the levels
of total u-PA antigen recovered in the ELISA
(r = 0.903, P6 0.001), indicating a simultaneous de-
crease of both u-PA activity and u-PA antigen (data
not shown). The e¡ect of thrombin on the recovery
of cell-bound u-PA may be explained by thrombin-
mediated release of u-PA bound to HUVEC, result-
ing in a decreased amount of cell-bound u-PA. To
correct for this phenomenon, levels of tcu-PA, scu-
PA and tcu-PA/T were expressed as a percentage of
the total amount of u-PA bound to HUVEC per
thrombin concentration (Fig. 1A).
Both the absolute levels of scu-PA (data not
shown) and the levels of scu-PA expressed as a per-
centage of total cell-bound u-PA were found to de-
crease with increasing amounts of thrombin (Fig.
1A). Simultaneously, tcu-PA/T was generated which
was re£ected both by an increase of absolute levels of
tcu-PA/T (data not shown) and an increase of tcu-
PA/T expressed as a percentage of total cell-bound u-
PA (Fig. 1A). Although the number of thrombin
concentrations tested is small, the data are compat-
ible with sigmoidal curves that were previously used
to describe the inactivation of scu-PA by thrombin in
solution [7,9]. About 0.2 nM thrombin was needed to
induce 50% inactivation of scu-PA. The levels of tcu-
PA were very low and were not a¡ected by throm-
bin, suggesting that scu-PA was hardly activated dur-
ing the incubation.
Fig. 1. Inactivation of HMW scu-PA by thrombin on HUVEC.
HMW scu-PA (1 Wg/ml) was bound to HUVEC (A) in four ex-
periments (n = 4) or to blank wells (B) in two experiments
(n = 2) for 30 min at 37‡C and subsequently incubated with in-
creasing amounts of thrombin for 30 min at 37‡C. Levels of
cell-bound tcu-PA (R), scu-PA (b) and tcu-PA/T (F) were
measured in bioimmunoassays (see Section 2) and were ex-
pressed as a percentage (mean þ S.D., n = 4) of the total amount
of cell-bound u-PA per thrombin concentration (see Table 1).
Levels of tcu-PA (O), scu-PA (a) and tcu-PA/T (E) bound to
the blank wells were measured as described above and were ex-
pressed as a percentage (mean, n = 2) of the total amount of
plastic-bound u-PA per thrombin concentration (see Table 1).
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About 10% binding of HMW u-PA to the blank
wells was found as compared with binding to HU-
VEC in the absence of thrombin (Table 1). scu-PA
bound to the blank wells was also found to be in-
activated by thrombin, but to a lesser extent than
scu-PA bound to HUVEC (Fig. 1B). In the blank
wells, 50% inactivation was not even reached at the
highest concentration of thrombin used (10 nM).
In the absence of thrombin, about 5% binding of
LMW scu-PA to HUVEC was found as compared
with HMW scu-PA (Table 1). Thrombin did not af-
fect the recovery of bound LMW u-PA in the BIAs.
The binding of LMW scu-PA to HUVEC was about
twofold higher than the binding of LMW scu-PA to
blank wells (Table 1).
These ¢ndings implied that in this experimental
set-up about 90% of the binding of HMW scu-PA
to HUVEC was speci¢c and mediated via the N-ter-
minal part of scu-PA. In addition, scu-PA bound to
HUVEC via cellular binding sites was more e⁄-
ciently inactivated by thrombin than scu-PA bound
to blank wells without HUVEC.
3.2. Role of the urokinase receptor in the inactivation
of scu-PA by thrombin on HUVEC
To examine speci¢cally whether scu-PA bound to
the urokinase receptor could be inactivated by
thrombin, we studied in a second experiment the
e¡ect of monoclonal anti-urokinase receptor IgG
(Moab H-2) on the inactivation of HMW scu-PA
by thrombin. The binding of HMW scu-PA to HU-
VEC was inhibited by Moab H-2 in a concentration-
dependent manner (Fig. 2A). At 10 Wg/ml monoclo-
nal antibody, 50% inhibition of scu-PA binding was
found. This ¢nding indicated that in this experimen-
tal set-up at least 50% of HMW scu-PA is bound to
HUVEC via the urokinase receptor. Since cell-bound
HMW scu-PA could be completely inactivated by
10 nM thrombin (Fig. 1A), the urokinase receptor
must be at least partially involved in this process.
The involvement of the urokinase receptor in the
inactivation of cell-bound scu-PA by thrombin was
con¢rmed by the ¢nding that the relative amount of
generated tcu-PA/T was not a¡ected by Moab H-2
(Fig. 2B). If only scu-PA bound to HUVEC via oth-
er binding sites than the urokinase receptor had been
inactivated by thrombin, then an increase in the rel-
ative amount of generated tcu-PA/T could have been
expected in the presence of Moab H-2.
4. Discussion
In this study, thrombin-mediated inactivation of
scu-PA bound to HUVEC was examined. Cell-bound
scu-PA was almost completely inactivated into tcu-
PA/T by 10 nM thrombin. In this experimental set-
up, at least 50% of the binding of scu-PA to HUVEC
appeared to be mediated by the urokinase receptor.
Fig. 2. E¡ect of monoclonal anti-urokinase receptor IgG
(Moab H-2) on the binding of HMW scu-PA to HUVEC and
on the inactivation of scu-PA by thrombin on HUVEC. HMW
scu-PA (1 Wg/ml) was bound to HUVEC in the absence (open
bars) and presence of 2.5 Wg/ml (hatched bars) or 10 Wg/ml (sol-
id bars) Moab H-2 for 30 min at 37‡C in three experiments
(n = 3). Subsequently, cell-bound scu-PA was incubated with
0.1 nM thrombin for 30 min at 37‡C. Levels of cell-bound tcu-
PA, scu-PA and tcu-PA/T were measured in bioimmunoassays
(see Section 2). The total amount of bound u-PA (mean þ S.D.,
n = 3) was expressed as the sum of the amounts of tcu-PA, scu-
PA and tcu-PA/T (A) and generated tcu-PA/T was expressed as
a percentage of the total amount of bound u-PA (B).
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The involvement of other binding sites besides the
urokinase receptor, like gangliosides and glycosami-
noglycans cannot be excluded [28^31]. From our re-
sults it is concluded that binding of scu-PA to HU-
VEC via the urokinase receptor o¡ers no protection
against inactivation, as has been claimed for the
binding of scu-PA to soluble urokinase receptor by
Wilhelm et al. [32]. An explanation may be that due
to the binding of thrombin to an endothelial cofac-
tor, a possible protective e¡ect of the urokinase re-
ceptor is abolished. In the study of Wilhelm et al.,
thrombin bound to its cofactor thrombomodulin was
capable of inactivating urokinase receptor-bound
scu-PA [32].
Cell-bound scu-PA was more e⁄ciently inactivated
by thrombin than plastic-bound scu-PA in the same
experiments. About 0.2 nM thrombin was needed to
induce 50% inactivation of cell-bound scu-PA, and
more than 10 nM thrombin to induce 50% inactiva-
tion of plastic-bound scu-PA. Previous studies have
shown that in the absence of thrombomodulin, 50%
inactivation of scu-PA in bu¡er is induced by 5^15
nM thrombin [7,9]. In the presence of thrombomo-
dulin, about 0.2^1 nM thrombin is needed to induce
50% inactivation in bu¡er [7,9]. These data suggest
that the inactivation of cell-bound scu-PA by throm-
bin may be potentiated by a cofactor like thrombo-
modulin. Thrombomodulin is an endothelial cofactor
for thrombin and potentiates the activation of pro-
tein C and thrombin activatable ¢brinolysis inhibitor
by thrombin at the endothelial cell surface [11,33^
35]. Molinari et al. have demonstrated that endoge-
nous thrombomodulin enhances the inactivation of
scu-PA by thrombin in a perfused rabbit heart model
[8]. In addition to thrombomodulin, other compo-
nents on the endothelial surface may serve as a co-
factor for thrombin. It is known that heparin and
related glycosaminoglycans like heparan sulfate and
chondroitin sulfate potentiate the inactivation of scu-
PA by thrombin [8,36]. Heparin-like molecules are
present on endothelial cells and are able to bind
both thrombin and u-PA [30,31,37^39]. Further re-
search is needed to examine the role of thrombomo-
dulin or other cofactors like glycosaminoglycans in
the inactivation of cell-bound scu-PA by thrombin.
A strong and rapid decreasing e¡ect of thrombin
on the recovery of cell-bound u-PA was observed.
This observation may be explained by the release
of the urokinase receptor from HUVEC by thrombin
[40]. Cleavage of the ligand-binding domains of the
urokinase receptor by tcu-PA as described by Hoyer-
Hansen et al. [41] is not likely, since no activation of
scu-PA into active tcu-PA was observed.
The inactivation of cell-bound scu-PA seems not
to be restricted to a speci¢c cell type. In a prelimi-
nary experiment, we found that scu-PA bound to
cultured human smooth muscle cells is also inacti-
vated by thrombin (unpublished observations). Re-
cently, it was demonstrated that scu-PA associated to
human platelets via an unidenti¢ed urokinase bind-
ing protein is inactivated by thrombin into tcu-PA/T.
This reaction is followed by re-activation of tcu-PA/
T due to thrombin-mediated release of a lysosomal
enzyme by platelets [42]. This phenomenon may be
of importance for the regulation of ¢brinolysis. Be-
sides on ¢brinolysis, thrombin-mediated inactivation
of cell-bound scu-PA may have profound e¡ects on
processes in which both u-PA and thrombin are in-
volved, like angiogenesis, atherosclerosis and re-
stenosis.
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